We are live on ! Find out more
CLVS

Clovis Oncology, Inc.
CLVS

Delisted

CLVS was delisted on the 20th of December, 2022.

Back to rankings

1 hedge funds and large institutions have $11K invested in Clovis Oncology, Inc. in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CAS
Coppell Advisory Solutions
Texas
+$11K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CAS
1
Coppell Advisory Solutions
Texas
$11K +$11K +229 New

CLVS Hedge Fund Activity: Q3 2023 in Review

1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2023, worth a combined $11K.

Buyers outnumbered sellers: 1 fund opened new CLVS positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Coppell Advisory Solutions, opening a new position worth an estimated $11K.

  • 1 institutional investor held Clovis Oncology, Inc. (CLVS) as of Q3 2023, up from 0 in Q2 2023.
  • Funds reported $11K of Clovis Oncology, Inc. stock for Q3 2023.
  • 1 fund opened new Clovis Oncology, Inc. positions in Q3 2023 and 0 closed out, a net change of +1 holder.
  • The largest Clovis Oncology, Inc. buyer in Q3 2023 was Coppell Advisory Solutions, an estimated $11K added.

Based on aggregated 13F filings for Q3 2023.